World biomedical experts to attend J'lem conference

Israel Academy of Sciences and the Arts jubilee to center on topics ranging from genome-specific cancer treatment to infectious diseases.

April 29, 2010 04:48
1 minute read.
Genome-specific cancer treatments will be one of t

genome specific treatment 311. (photo credit: Courtesy)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Nine of the world’s leading innovators in biomedicine from Israel, the US and Europe are due to meet at the Israel Academy of Sciences and the Arts on Monday and Tuesday for a conference that will mark the academy’s 50th anniversary.

The participants will discuss a variety of new subjects, from the customization of treatments to suit the individual genome of patients suffering from cancer to infectious diseases. The academy will call on Israel to join the world effort to identify the genomes of individual patients and become part of the global effort to improve medical treatments.

Among those participating will be Prof. Ada Yonath, Israel’s most recent Nobel Prize winner in chemistry, from the Weizmann Institute of Science in Rehovot. The other participants are Prof. Arthur Beaudet, chairman of the department of molecular and human genetics at Baylor College of Medicine in Texas; Prof. Leroy Hood, president of the Institute for Systems Biology in Seattle; Prof. Fotis Kafatos, chairman of immunogenomics at the Imperial College London; Prof. Mary-Claire King of the departments of medicine and genome sciences at the University of Washington School of Medicine in Seattle; Prof. Eric Lander,
president of the Broad Institute of the Massachusetts Institute of Technology and professor of systems biology at Harvard Medical School; Prof. Matthias Mann, director of the Max Planck Institute of Biochemistry in the department of proteomics and signal transduction in Martinsried, Germany; Prof. Rino Rappuoli, global head of vaccines research at Novartis Vaccines and Diagnostics in Siena, Italy; Prof. Michel Revel of the Weizmann Institute’s department of molecular genetics and chairman of the Israel National Bioethics Council; Prof. David Scadden, co-director of the Harvard Stem Cell Institute and director of the Center for Regenerative Medicine at Massachusetts General Hospital; and Prof. Axel Ullrich of the department of molecular biology at Max Planck.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia